Finally, HER2+ breast tumors treated with trastuzumab plus anthracyclines exhibit increased Th1/CTL-driven immunity relative to chemotherapy alone (Ladoire et al., 2011). This evidence concerns the gene ERBB2 and breast neoplasm.